Puri PDRN

Puri PDRN 2.5ml x 5 is a cutting-edge rejuvenating solution formulated to enhance skin elasticity, density, and long-lasting hydration. Backed by advanced nucleic acid technology and clinical validation, PURI PDRN combines pharmaceutical-grade Polynucleotides (PDRN, 5mg/ml) with Cross-linked Hyaluronic Acid (25mg/ml) to deliver visible anti-aging and regenerative benefits.

Key Benefits

• Dermal Density Improvement – Increases collagen density by 42% after 16 weeks (3D skin scanning, n=120).

• Wrinkle Depth Reduction – Reduces vertical wrinkle depth by 57% (PRIMOS 3D analysis).

• Pore Size Minimization – Achieves up to 39% reduction in pore diameter after 4 treatments.

• Skin Brightening – Improves brightness by 5.1% (L* value, Chroma Meter CR-400).

• Deep Hydration & Elasticity – Hyaluronic acid absorbs up to 1000x its weight in water for long-term moisturization.

Treatment Timeline

• Stage 1: Initial Treatment (2 sessions, 2-week intervals): Rapid hydration, smoother texture, 89% of users report visible brightness improvement within 14 days.

• Stage 2: Collagen Induction (Sessions 3–4, 3-week intervals): Promotes measurable dermal thickening (+0.23mm on ultrasound), with 72% elasticity improvement.

• Maintenance Phase: Quarterly sessions sustain 83% of collagen gains, recommended in combination with Potenza RF for enhanced pore reduction.

Pharmaceutical Specifications

• Active Ingredients: PDRN 5mg/ml + HA 25mg/ml

• Packaging: 5 x 2.5ml sterile ampoules

• Molecular Weight: 500–1500 Da PDRN fragments

• Sterility: Terminal sterilization at 121°C for 15 minutes

• Storage: 2–25°C, protected from light

• Shelf Life: 24 months unopened

Clinical Protocol

• Needle Size: 31–34G (5/9 needle mesogun)

• Depth: 1.2–2.4mm (epidermal–dermal junction)

• Frequency: Every 2–3 weeks

• Course: 4 sessions recommended for optimal results

• Dosage: 0.5–1ml per treatment area

Medical Advisory

• For professional dermatological use only.

• Contraindications: active skin infections, pregnancy, history of keloid formation, or patients undergoing radiation therapy.

• Post-treatment erythema typically resolves within 24–48 hours. Discontinue use if persistent hypersensitivity occurs.